Alignment Healthcare (NASDAQ:ALHC – Get Free Report) and OPKO Health (NASDAQ:OPK – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.
Profitability
This table compares Alignment Healthcare and OPKO Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alignment Healthcare | 0.89% | 20.02% | 3.46% |
| OPKO Health | -12.40% | -5.88% | -3.83% |
Insider and Institutional Ownership
86.2% of Alignment Healthcare shares are held by institutional investors. Comparatively, 64.6% of OPKO Health shares are held by institutional investors. 5.2% of Alignment Healthcare shares are held by company insiders. Comparatively, 44.7% of OPKO Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Analyst Ratings
This is a summary of recent ratings and recommmendations for Alignment Healthcare and OPKO Health, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alignment Healthcare | 0 | 4 | 7 | 0 | 2.64 |
| OPKO Health | 1 | 4 | 1 | 0 | 2.00 |
Alignment Healthcare currently has a consensus price target of $23.60, suggesting a potential upside of 70.71%. OPKO Health has a consensus price target of $1.55, suggesting a potential upside of 11.91%. Given Alignment Healthcare’s stronger consensus rating and higher probable upside, analysts clearly believe Alignment Healthcare is more favorable than OPKO Health.
Earnings and Valuation
This table compares Alignment Healthcare and OPKO Health”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alignment Healthcare | $3.95 billion | 0.73 | -$720,000.00 | $0.19 | 72.76 |
| OPKO Health | $606.90 million | 1.70 | -$225.68 million | ($0.09) | -15.39 |
Alignment Healthcare has higher revenue and earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Alignment Healthcare, indicating that it is currently the more affordable of the two stocks.
Summary
Alignment Healthcare beats OPKO Health on 11 of the 14 factors compared between the two stocks.
About Alignment Healthcare
Alignment Healthcare, Inc., a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.
About OPKO Health
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
Receive News & Ratings for Alignment Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alignment Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
